INOmax, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of newborns ≥ 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation.